PT3043785T - Aplicação de r-cetamina e seu sal como medicamentos - Google Patents

Aplicação de r-cetamina e seu sal como medicamentos

Info

Publication number: PT3043785T
Authority: PT; Portugal
Prior art keywords: ketamine; pharmaceuticals; salt; application
Prior art date: 2013-09-13

Application number

PT147933196T

Other languages

English (en)

Original Assignee

Univ Chiba Nat Univ Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-09-13

Filing date

2014-09-12

Publication date

2021-11-05

2014-09-12 Application filed by Univ Chiba Nat Univ Corp filed Critical Univ Chiba Nat Univ Corp

2021-11-05 Publication of PT3043785T publication Critical patent/PT3043785T/pt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Epidemiology (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Anesthesiology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)

PT147933196T 2013-09-13 2014-09-12 Aplicação de r-cetamina e seu sal como medicamentos PT3043785T (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP2013190066		2013-09-13

Publications (1)

Publication Number	Publication Date
PT3043785T true PT3043785T (pt)	2021-11-05

Family

ID=51846870

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT147933196T PT3043785T (pt)	2013-09-13	2014-09-12	Aplicação de r-cetamina e seu sal como medicamentos

Country Status (16)

Country	Link
US (5)	US9872841B2 (pt)
EP (2)	EP3043785B1 (pt)
JP (7)	JP6366439B2 (pt)
CA (2)	CA2923685C (pt)
CY (1)	CY1125290T1 (pt)
DK (1)	DK3043785T3 (pt)
ES (1)	ES2897453T3 (pt)
HR (1)	HRP20211629T1 (pt)
HU (1)	HUE056378T2 (pt)
LT (1)	LT3043785T (pt)
PL (1)	PL3043785T3 (pt)
PT (1)	PT3043785T (pt)
RS (1)	RS62516B1 (pt)
SI (1)	SI3043785T1 (pt)
SM (1)	SMT202100641T1 (pt)
WO (1)	WO2015037248A1 (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2755809T3 (es)	2013-03-15	2020-04-23	Janssen Pharmaceutica Nv	Composición farmacéutica de hidrocloruro de S-ketamina
RS62516B1 (sr) *	2013-09-13	2021-11-30	Univ Chiba Nat Univ Corp	Primena r-ketamina i njegove soli kao farmaceutskih proizvoda
WO2016044150A1 (en)	2014-09-15	2016-03-24	Janssen Pharmaceutica Nv	VAL66MET (SNP rs6265) GENOTYPE SPECIFIC DOSING REGIMENS AND METHODS FOR THE TREATMENT OF DEPRESSION
US20160332962A1 (en) *	2015-05-13	2016-11-17	Janssen Pharmaceutica Nv	(s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
JP6845162B2 (ja)	2015-06-27	2021-03-17	シェノックス・ファーマシューティカルズ・エルエルシー	ケタミン経皮送達システム
WO2017087691A1 (en)	2015-11-17	2017-05-26	The Trustees Of Columbia University In The City Of New York	Pharmacological prophylactics against stress-induced affective disorders and their associated symptoms
AU2017351437B2 (en)	2016-10-27	2022-01-27	National University Corporation Chiba University	Application of (S)-norketamine and salt thereof as pharmaceutical
JP2021003001A (ja) *	2017-09-07	2021-01-14	国立大学法人千葉大学	うつ症状の検査方法、及び治療薬のスクリーニング方法
US20200009081A1 (en)	2017-09-13	2020-01-09	Janssen Pharmaceutica N.V.	Delivery Of Esketamine For The Treatment Of Depression
TW201919595A (zh) *	2017-09-27	2019-06-01	國立大學法人千葉大學	作為神經變性疾病或認知機能障礙之預防或治療劑之r-氯胺酮及其衍生物
US11491120B2 (en)	2017-11-09	2022-11-08	The Trustees Of Columbia University In The City Of New York	Pharmacological prophylactics against stress-induced affective disorders in females
US11622948B2 (en)	2017-11-09	2023-04-11	The Trustees Of Columbia University In The City Of New York	Biomarkers for efficacy of prophylactic treatments against stress-induced affective disorders
BR112020012473A2 (pt)	2017-12-22	2020-11-24	Janssen Pharmaceuticals, Inc.	escetamina para o tratamento da depressão
PL3505157T3 (pl)	2017-12-29	2022-04-11	Celon Pharma S.A.	Kompozycja ketaminy w postaci suchego proszku do podawania dopłucnego w leczeniu depresji opornej na leczenie
EP3753557B1 (en) *	2018-02-15	2025-11-05	National University Corporation Chiba University	Preventive or therapeutic agent and pharmaceutical composition for inflammatory diseases or bone diseases
CA3099293A1 (en) *	2018-05-04	2019-11-07	Perception Neuroscience, Inc.	Methods of treating substance abuse
US11154537B2 (en)	2018-08-10	2021-10-26	Eleusis Therapeutics Us, Inc.	Method of treatment for ketamine infusion
JP7483630B2 (ja) *	2018-12-27	2024-05-15	国立大学法人千葉大学	神経発達障害の予防または治療剤としてのｒ－ケタミンおよびその誘導体
CN114126595A (zh)	2019-03-05	2022-03-01	杨森制药公司	用于治疗抑郁症的艾司氯胺酮
CA3133012A1 (en) *	2019-08-05	2021-02-11	The Ketamine Research Foundation	Ketamine for the treatment of postpartum symptoms and disorders
CN112125816A (zh) *	2020-03-17	2020-12-25	国药集团工业有限公司	一种氯胺酮、其衍生物或其盐的消旋化方法
WO2021195627A1 (en) *	2020-03-27	2021-09-30	Homeostasis Therapeutics, Limited	Method of treatment for anorexia nervosa, bulimia and related clinical syndromes
CN114306219B (zh) *	2020-09-30	2023-09-26	四川普锐特药业有限公司	稳定的r-氯胺酮药物组合物
WO2022118783A1 (ja) *	2020-12-04	2022-06-09	国立大学法人大阪大学	治療抵抗性うつ病または緊急性を有するうつ病の症状を治療するための組成物
US20240336556A1 (en)	2021-10-12	2024-10-10	Perception Neuroscience, Inc.	R-ketamine salts and methods of use thereof
JP2025509517A (ja)	2022-03-14	2025-04-11	パーセプションニューロサイエンス，インコーポレイティド	Ｒ－ケタミンの医薬製剤
CN115006375A (zh) *	2022-06-24	2022-09-06	华中科技大学	艾司氯胺酮用于制备治疗社交障碍药物的应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3254124A (en)	1962-06-29	1966-05-31	Parke Davis & Co	Aminoketones and methods for their production
CH535201A (de)	1969-12-19	1973-03-31	Bristol Myers Co	Verfahren zur Spaltung von racemischen 2-(o-Chlorphenyl)-2-methylaminocyclohexanon in die optisch-aktiven Isomeren
US4670459A (en)	1984-10-03	1987-06-02	Merrell Dow Pharmaceuticals Inc.	Method of alleviating withdrawal symptoms
US5679714A (en)	1995-06-07	1997-10-21	Weg; Stuart L.	Administration of ketamine for detoxification and treatment of tobacco addiction
US5543434A (en)	1994-02-25	1996-08-06	Weg; Stuart L.	Nasal administration of ketamine to manage pain
DE19619665C2 (de)	1996-05-15	2001-03-08	Goedecke Ag	Racemattrennung von Ketamin
US7001609B1 (en)	1998-10-02	2006-02-21	Regents Of The University Of Minnesota	Mucosal originated drug delivery systems and animal applications
US6382204B1 (en)	1999-10-14	2002-05-07	Becton Dickinson And Company	Drug delivery system including holder and drug container
US6962151B1 (en)	1999-11-05	2005-11-08	Pari GmbH Spezialisten für effektive Inhalation	Inhalation nebulizer
MXPA02008144A (es)	2000-02-23	2002-11-29	Amgen Inc	Agentes de enlace selectivos antagonistas de la proteina de enlace de osteoprotegerina.
BRPI0002693B8 (pt)	2000-06-19	2021-05-25	Cristalia Produtos Quim Farmaceuticos Ltda	processo de obtenção dos enantiômeros da cetamina e seus sais farmaceuticamente aceitáveis
US7090830B2 (en)	2001-05-24	2006-08-15	Alexza Pharmaceuticals, Inc.	Drug condensation aerosols and kits
MXPA05000294A (es)	2002-07-30	2005-08-19	Peter Migaly	Terapia combinada para la depresion, prevencion de suicidios y varias condiciones medicas y psiquiatricas.
US7273889B2 (en)	2002-09-25	2007-09-25	Innovative Drug Delivery Systems, Inc.	NMDA receptor antagonist formulation with reduced neurotoxicity
AU2003291037A1 (en)	2002-11-18	2004-06-15	Yaupon Therapeutics, Inc.	Analgesic uses of norketamine and ketamine/norketamine prodrugs
US7713440B2 (en)	2003-10-08	2010-05-11	Lyotropic Therapeutics, Inc.	Stabilized uncoated particles of reversed liquid crystalline phase materials
CN101309667A (zh)	2005-09-28	2008-11-19	奥里斯医学股份有限公司	治疗内耳疾病的药用合成物
CN101466364A (zh)	2006-03-22	2009-06-24	纽约大学西奈山医学院	鼻内施用氯胺酮治疗抑郁症
US20110038807A1 (en)	2009-08-14	2011-02-17	Demitri Papolos	Compositions and methods for treating bipolar disorder
US20120225949A1 (en)	2009-08-14	2012-09-06	Demitri Papalos	Compositions and methods for treating bipolar disorder
CN104519878A (zh)	2012-03-12	2015-04-15	詹森药业有限公司	用于治疗顽固性或难治性抑郁症的艾氯胺酮
KR20150096370A (ko)	2012-08-23	2015-08-24	스튜어트 엘. 웨그	항불안제 조성물, 제형 및 사용방법
ES2755809T3 (es)	2013-03-15	2020-04-23	Janssen Pharmaceutica Nv	Composición farmacéutica de hidrocloruro de S-ketamina
HUE045982T2 (hu)	2013-03-15	2020-01-28	Janssen Pharmaceutica Nv	S-Ketamin-hidroklorid gyógyászati kompozíció
KR20150142012A (ko)	2013-04-12	2015-12-21	이칸 스쿨 오브 메디슨 엣 마운트 시나이	외상후 스트레스 장애의 치료 방법
RS62516B1 (sr)	2013-09-13	2021-11-30	Univ Chiba Nat Univ Corp	Primena r-ketamina i njegove soli kao farmaceutskih proizvoda
WO2015108985A1 (en)	2014-01-14	2015-07-23	Children's Hospital Medical Center	Compositions comprising ketamine for treating an autism spectrum disorder
JP6545788B2 (ja)	2014-08-13	2019-07-17	ヤンセンファーマシューティカエヌ．ベー．	うつ病の治療方法
EP3085366A1 (en)	2015-04-22	2016-10-26	Institut du Cerveau et de la Moelle Epiniere-ICM	Nmda antagonists for the treatment of mental disorders with occurrence of aggressive and/or impulsive behavior
WO2016186968A1 (en)	2015-05-15	2016-11-24	The Arizona Board Of Regents On Behalf Of The University Of Arizona	Compositions and methods for treating motor disorders
WO2017087691A1 (en)	2015-11-17	2017-05-26	The Trustees Of Columbia University In The City Of New York	Pharmacological prophylactics against stress-induced affective disorders and their associated symptoms
TW201919595A (zh)	2017-09-27	2019-06-01	國立大學法人千葉大學	作為神經變性疾病或認知機能障礙之預防或治療劑之r-氯胺酮及其衍生物
EP3753557B1 (en)	2018-02-15	2025-11-05	National University Corporation Chiba University	Preventive or therapeutic agent and pharmaceutical composition for inflammatory diseases or bone diseases
CA3099293A1 (en)	2018-05-04	2019-11-07	Perception Neuroscience, Inc.	Methods of treating substance abuse
JP7483630B2 (ja)	2018-12-27	2024-05-15	国立大学法人千葉大学	神経発達障害の予防または治療剤としてのｒ－ケタミンおよびその誘導体
US10973780B2 (en)	2019-05-15	2021-04-13	Bexson Biomedical, Inc.	Ketamine formulation for subcutaneous injection

2014
- 2014-09-12 RS RS20211346A patent/RS62516B1/sr unknown
- 2014-09-12 SM SM20210641T patent/SMT202100641T1/it unknown
- 2014-09-12 PL PL14793319T patent/PL3043785T3/pl unknown
- 2014-09-12 DK DK14793319.6T patent/DK3043785T3/da active
- 2014-09-12 EP EP14793319.6A patent/EP3043785B1/en active Active
- 2014-09-12 ES ES14793319T patent/ES2897453T3/es active Active
- 2014-09-12 HR HRP20211629TT patent/HRP20211629T1/hr unknown
- 2014-09-12 CA CA2923685A patent/CA2923685C/en active Active
- 2014-09-12 US US15/021,003 patent/US9872841B2/en active Active
- 2014-09-12 JP JP2014186056A patent/JP6366439B2/ja active Active
- 2014-09-12 CA CA3143962A patent/CA3143962A1/en active Pending
- 2014-09-12 WO PCT/JP2014/004730 patent/WO2015037248A1/en not_active Ceased
- 2014-09-12 EP EP21192664.7A patent/EP3964203A1/en active Pending
- 2014-09-12 SI SI201431903T patent/SI3043785T1/sl unknown
- 2014-09-12 LT LTEPPCT/JP2014/004730T patent/LT3043785T/lt unknown
- 2014-09-12 HU HUE14793319A patent/HUE056378T2/hu unknown
- 2014-09-12 PT PT147933196T patent/PT3043785T/pt unknown
2017
- 2017-12-21 US US15/849,698 patent/US10406121B2/en active Active
2018
- 2018-07-03 JP JP2018126684A patent/JP6615277B2/ja active Active
2019
- 2019-07-26 US US16/522,815 patent/US11207279B2/en active Active
- 2019-11-01 JP JP2019199496A patent/JP6842206B2/ja active Active
2021
- 2021-02-11 JP JP2021020280A patent/JP2021073310A/ja active Pending
- 2021-11-16 US US17/527,693 patent/US20220071929A1/en not_active Abandoned
- 2021-11-24 CY CY20211101022T patent/CY1125290T1/el unknown
2022
- 2022-11-27 JP JP2022188797A patent/JP7398836B2/ja active Active
2023
- 2023-11-28 JP JP2023200421A patent/JP7627514B2/ja active Active
- 2023-12-19 US US18/545,395 patent/US20240382436A1/en active Pending
2025
- 2025-01-20 JP JP2025007274A patent/JP2025061458A/ja active Pending

Also Published As

Publication number	Publication date
JP7627514B2 (ja)	2025-02-06
PL3043785T3 (pl)	2022-02-28
US20240382436A1 (en)	2024-11-21
EP3043785A1 (en)	2016-07-20
US9872841B2 (en)	2018-01-23
JP6615277B2 (ja)	2019-12-04
JP6842206B2 (ja)	2021-03-17
JP2025061458A (ja)	2025-04-10
ES2897453T3 (es)	2022-03-01
JP2024009274A (ja)	2024-01-19
LT3043785T (lt)	2021-12-10
US20220071929A1 (en)	2022-03-10
US20180177745A1 (en)	2018-06-28
JP2021073310A (ja)	2021-05-13
US20160220513A1 (en)	2016-08-04
CA2923685C (en)	2022-03-08
RS62516B1 (sr)	2021-11-30
JP2015078181A (ja)	2015-04-23
JP2018145207A (ja)	2018-09-20
DK3043785T3 (da)	2021-11-15
US10406121B2 (en)	2019-09-10
JP2023011027A (ja)	2023-01-20
JP2020015766A (ja)	2020-01-30
US20190343781A1 (en)	2019-11-14
HUE056378T2 (hu)	2022-02-28
EP3964203A1 (en)	2022-03-09
HRP20211629T1 (hr)	2022-02-04
CA2923685A1 (en)	2015-03-19
JP7398836B2 (ja)	2023-12-15
CA3143962A1 (en)	2015-03-19
SMT202100641T1 (it)	2022-01-10
US11207279B2 (en)	2021-12-28
SI3043785T1 (sl)	2022-02-28
CY1125290T1 (el)	2023-03-24
WO2015037248A1 (en)	2015-03-19
EP3043785B1 (en)	2021-08-25
JP6366439B2 (ja)	2018-08-01

Publication	Publication Date	Title
PT3043785T (pt)	2021-11-05	Aplicação de r-cetamina e seu sal como medicamentos
IL274355B (en)	2021-02-28	Aza-pyridone compounds and their uses
IL243608A0 (en)	2016-02-29	Substances with antiviral activity, preparations containing them and their uses
GB201323008D0 (en)	2014-02-12	Compounds and uses thereof
IL240178A (en)	2016-08-31	N - (4-Azoindazole-6-ram) -Penyl) Sulphonamidine and their use as Pharmaceuticals
SG11201507897SA (en)	2015-11-27	Salt of pyrazoloquinoline derivative, and crystal thereof
SG11201506713TA (en)	2015-09-29	2-acylaminothiazole derivative and salt thereof
EP3054974A4 (en)	2017-06-14	Glycan-interacting compounds and methods of use
PT2967044T (pt)	2018-02-27	Composição herbicida e seu método de uso
IL243615A0 (en)	2016-02-29	Consequences of mutated pyrazolylpyrazole and its use as a herbicide
IL243614A0 (en)	2016-02-29	Consequences of mutated pyrazolylpyrazole and its use as a herbicide
IL243613B (en)	2019-01-31	Consequences of mutated pyrazolylpyrazole and its use as a herbicide
GB201307233D0 (en)	2013-05-29	Compounds and uses thereof
TWI562776B (en)	2016-12-21	Pharmaceutical composition and uses thereof
GB201312698D0 (en)	2013-08-28	Preparation and use of zinc compounds
GB201307082D0 (en)	2013-05-29	Pharmaceutical composition comprising 15-HETrE and methods of using the same
GB201309180D0 (en)	2013-07-03	Compounds and Their Uses
IL240177A (en)	2016-08-31	Chromium-6-Iloxy-cycloalkanes are conserved and used as drugs
GB201314610D0 (en)	2013-10-02	Compounds and their uses
GB201306248D0 (en)	2013-05-22	Compounds and their uses
IL240447A0 (en)	2015-09-24	Propionic-biaryl acid derivatives and their use as pharmaceutical preparations
IL243616A0 (en)	2016-02-29	Consequences of mutated pyrazolylpyrazole and its use as a herbicide
GB201518882D0 (en)	2015-12-09	Agrochemical composition and method of use thereof
IL240422A0 (en)	2015-09-24	Bi-aryl derivatives of propionic acid and their use as medicinal preparations
EP3052475A4 (en)	2017-05-03	Pharmaceutical use of 3-benzylsulfonylpropionitrile